Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
GLP medications work by targeting hormones that regulate appetite, blood sugar, digestion, and energy balance
Our IHC studies on human and mouse islets confirmed our DART-Seq findings that liraglutide increases bihormonal insulin + glucagon + cells
Licorice soothes throughout
Conclusion (Summary first) GLP-1 receptor agonists may increase the risk of cholelithiasis and gallbladder disease The risk is tending to be higher with drugs and dosages that cause greater weight loss The mechanism is reduced gallbladder motility + rapid weight loss Cholelithiasis risk: Overall picture In large-scale meta-analyses, GLP-1 receptor agonist use Gallbladder disease risk: RR 1.37 Cholelithiasis: RR 1.27 Cholecystitis: RR 1.36 1) It is important to note that while this is a significant increase, the "absolute risk is not high." Differences in risk by drug Liraglutide (Victoza) The increase in cholelithiasis risk is relatively clear In the SCALE trials, Gallstone-related events: 2.3% vs 1.0% (placebo) 2) Increased in the group with greater weight loss Semaglutide (Ozempic/Wegovy) In the STEP trials, etc., Gallbladder disease increasing trend (approx
Support your skin through weight loss Skincare created for skin experiencing visible change during GLP-1 journeys, weight loss and body transformation
US$ 28.70
US$ 28.92
US$ 22.78
US$ 26.11
US$ 22.30
US$ 26.98
US$ 24.22
